109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
METHODS FOR TREATING SPINAL CORD INJURY
#1802TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1803METHOD FOR TREATING CARDIOVASCULAR DISEASE
#1804Oligonucleotide comprising an inosine for treating DMD
#1805IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
#1806INHIBITION OF CATALYTIC SITE COMMON TO MULTIPLE 3 ALPHA-OXIDOREDUCTASES FOR TREATMENT OF PROSTATE CANCER
#1807Methods of improving anemias by combining agents
#1808Antisense oligonucleotides and their use for treating Pendred syndrome
#1809Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
#1810Systems and methods for determining effects of therapies and genetic variation on polyadenylation site selection
#1811GUAYULE WITH INCREASED RUBBER PRODUCTION AND YIELD
#1812Oligonucleotides for modulating SCN9A expression
#1813PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
#1814BETA CATENIN NUCLEIC ACID INHIBITOR MOLECULE
#1815Oligonucleotide Conjugates
#1816Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors
#1817Chemically modified single-stranded RNA-editing oligonucleotides
#1818PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR
#1819Chimeric RNA-driven genomic rearrangement in mammalian cells
#1820Selective antisense compounds and uses thereof
#1821Staufen1 regulating agents and associated methods
#1822Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
#1823Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1824Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
#1825OLIGONUCLEOTIDES FOR CONTROLLING TAU SPLICING, AND USES THEREOF
#1826Methods of reducing virus molecule levels
#1827Stereospecific linkages in RNA editing oligonucleotides
#1828Compositions for Modulating C9ORF72 Expression
#1829COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS
#1830MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#1831LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1832Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1833THERAPEUTIC AGENT FOR CARTILAGE-RELATED DISEASE
#1834POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF
#1835COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANESTHESIA-INDUCED NEUROTOXICITY
#1836ANTISENSE NUCLEIC ACIDS
#1837AMYGDALAR NEURAL ENSEMBLE THAT ENCODES THE UNPLEASANTNESS OF PAIN
#1838Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#1839EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#1840ENHANCED OLIGONUCLEOTIDES FOR INHIBITING SCN9A EXPRESSION
#1841Peptide docking vehicle for targeted nucleic acid delivery
#1842COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#1843Compositions and methods for treating pancreatitis
#1844Treatments of non-alcoholic steatohepatitis (NASH)
#1845Compositions and methods for modulating growth hormone receptor expression
#1846Methods of Treating Celiac Disease Using SMAD7 Inhibition
#1847Methods and compositions for inhibiting detoxification response
#1848MYOCARDIAL DYSFUNCTION THERAPEUTIC AGENT
#1849METHODS FOR DETERMINING THE PRESENCE OR RISK OF DEVELOPING FACIOSCAPULOHUMERAL DYSTROPHY (FSHD)
#1850Methods of treating cancer and/or enhancing sensitivity to cancer treatment by increasing tumor mutation burden or tumor indels
#1851Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
#1852Methods and formulations for the treatment of obesity and obesity-related metabolic diseases
#1853ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#1854Antisense nucleic acids
#1855Compositions and methods for treating eye disorders
#1856SELF-MANAGEABLE ABNORMAL SCAR TREATMENT WITH SPHERICAL NUCLEIC ACID (SNA) TECHNOLOGY
#1857METHODS OF MODULATING ANK1
#1858ENHANCED REPROGRAMMING OF SOMATIC CELLS
#1859SINGLE-STRANDED NUCLEIC ACID MOLECULE, AND PRODUCTION METHOD THEREFOR
#1860EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
#1861Methods of treating cancers
#1862Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#1863Exon skipping compositions for treating muscular dystrophy
#1864ANTI-ARID3A TREATMENTS FOR INFLAMMATORY DISORDERS
#1865Modulating SYNGAP
#1866Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#1867MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#1868ANTISENSE NUCLEIC ACIDS
#1869Skin-permeating carrier containing nucleic acid complex and use thereof
#1870bZIP transcription factors regulate conversion of nicotine to nornicotine
#1871METHODS OF MODULATING ANTISENSE ACTIVITY
#1872Polyanionic acids to improve recovery and minimize system loss
#1873Use of SRSF3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
#1874Antisense nucleic acid targeting PCSK9
#1875Modulation of factor 11 expression
#1876METHODS FOR REDUCING C9ORF72 EXPRESSION
#1877POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#1878Methods of treating VEGF/VEGFR resistant prostate, renal, or colorectal cancers using combination therapies
#1879Modulation of alternative MDM2 splicing
#1880Agents useful in treating facioscapulohumeral muscular dystrophy
#1881AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1882CELLULAR COMPOSITIONS AND METHODS OF TREATMENT I
#1883METHODS OF CHANGING TRANSCRIPTIONAL OUTPUT
#1884Methods for Improving Leptin Sensitivity for the Treatment of Obesity and Diabetes
#1885Methods for targeting pain directed at metabolic pathways
#1886Antisense-induced exon exclusion in type VII collagen
#1887Modulation of gene expression and screening for deregulated protein expression
#1888Modulators of EZH2 expression
#1889ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS
#1890RNA-AIDED IMMUNOTHERAPEUTICS
#1891Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
#1892Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor
#1893Methods for treating multiple sclerosis using antisense oligonucleotides
#1894OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#1895ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#1896Antisense nucleic acids
#1897Selective Antisense Compounds and Uses Thereof
#1898Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#1899Oligonucleotides for reduction of PD-L1 expression
#1900CD71 binding fibronectin type III domains
#1901Antisense oligonucleotides useful in treatment of Pompe disease
#1902ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY
#1903Oligonucleotide therapy for Leber congenital amaurosis
#1904Modulation of Huntington expression
#1905Cancer chemoprevention with STAT3 blockers
#1906Structural domains of antisense RNA molecules up-regulating translation
#1907OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
#1908Peptide oligonucleotide conjugates
#1909Treatment of Fuchs' endothelial corneal dystrophy
#1910G-quadruplex-containing antisense oligonucleotides
#1911Exon skipping oligomer conjugates for muscular dystrophy
#1912Exon skipping oligomer conjugates for muscular dystrophy
#1913Treatment of aberrant fibroblast proliferation
#1914TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM
#1915LUNG-SPECIFIC DRUG DELIVERY SYSTEM CONSISTING OF OLIGONUCLEOTIDE POLYMERS AND BIOCOMPATIBLE CATIONIC PEPTIDES FOR THE PREVENTION OR TREATMENT OF PULMONARY FIBROSIS AND USE THEREOF
#1916Ischemic-lesion-site-specific gene therapy
#1917COMPOSITIONS AND METHODS
#1918Chiral control
#1919DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY
#1920Methods for treatment or prevention of leukemia
#1921Lipids for use in lipid nanoparticle formulations
#1922P-ethoxy nucleic acids for BCL2 inhibition
#1923Oligonucleotides for modulating Tau expression
#1924Antisense oligonucleotides for the treatment of usher syndrome type 2
#1925POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#1926Lipids for use in lipid nanoparticle formulations
#1927Lipids for use in lipid nanoparticle formulations
#1928Ferrochelatase inhibitors and methods of use
#1929P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION
#1930Tailored modulation of gene regulation programs via functional enhancer RNA
#1931CHANNEL MODULATORS
#1932O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
#1933Composition for delivering nucleic acid and nucleic acid-containing composition
#1934Antisense oligonucleotides for the treatment of Stargardt disease
#1935Thiophosphoramidites
#1936METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
#1937Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
#1938Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1939MODULATORS OF GROWTH HORMONE RECEPTOR
#1940TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
#1941OLIGONUCLEOTIDE DERIVATIVE OR SALT THEREOF
#1942MicroRNA Compounds and Methods for Modulating MIR-122
#1943RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#1944COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF
#1945FN3 domain-siRNA conjugates and uses thereof
#1946Cancer treatment by MALAT1 inhibition
#1947EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#1948SIRT1-saRNA compositions and methods of use
#1949Compositions and methods for modulating MECP2 expression
#1950Promotion of cardiomyocyte proliferation and regenerative treatment of the heart by inhibition of microRNA-128
#1951RNAi agents for hepatitis B virus infection
#1952FUNCTIONAL TARGETS OF MIR-6891-5P & APPLICATIONS THEREOF
#1953Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
#1954Modified oligonucleotides for use in treatment of tauopathies
#1955Modulation of transthyretin expression
#1956Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
#1957Micro RNA expression constructs and uses thereof
#1958ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1
#1959OLIGONUCLEOTIDES FOR MODULATING ERC1 EXPRESSION
#1960OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION
#1961OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION
#1962Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1963Compositions and methods for modulating apolipoprotein (a) expression
#1964ANTISENSE ANTIBIOTICS AND BACTERIAL SECRETION BASED DELIVERY SYSTEM TO ELIMINATE DRUG-RESISTANT BACTERIA
#1965Modulation of alpha synuclein expression
#1966Medicine for treating disorders of glucose and/or lipid metabolism and a method of treating glucose and/or lipid metabolic disorders
#1967Branched oligonucleotides
#1968Microrna and uses thereof in prevention and/or treatment of fibroplasia medical sign and/or syndrome
#1969Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1970Anti-connexin compounds targeted to connexins and methods of use thereof
#1971Modulators of APOL1 expression
#1972ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING
#1973Antisense oligonucleotide compositions
#1974Modulators of PCSK9 expression
#1975Exon skipping oligomer conjugates for muscular dystrophy
#1976NEURAL STEM CELL DELIVERY OF THERAPEUTIC AGENTS
#1977Methods for immunoregulation by modulating plasminogen-apple-nematode (PAN) domain-containing proteins
#1978Compositions for modulating Tau expression
#1979Methods and compositions for control of arthropod pests
#1980Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1981Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1982Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1983Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1984Methods and compositions for inhibiting expression of LDHA
#1985Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1986Compositions and uses for treatment thereof
#1987Methods and compositions for treating cancers using antisense
#1988Oligonucleotides for modulating TMEM106B expression
#1989Oligomers and oligomer conjugates
#1990ANTISENSE OLIGONUCLEOTIDE REDUCED IN TOXICITY
#1991Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33
#1992CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#1993BIODIFFUSION CHAMBER
#1994Liposomal particles, methods of making same and uses thereof
#1995Compositions Comprising Immune System Activators and Method of Using Same
#1996Pharmaceutical composition for treatment of diseases associated with upregulated periostin expression or periostin splice variant switching
#1997Methods of treating spinal muscular atrophy
#1998Modified oligonucleotides and methods of use
#1999Antisense molecules and methods for treating pathologies
#2000Compounds and methods for the modulation of amyloid-β precursor protein
#2001Method of treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or gluten hypersensitivity by administering an elastase 2A (ELA2A) inhibitor
#2002Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
#2003Lipid-derived neutral nanoparticles
#2004Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#2005Composition for suppressing inflammation
#2006Oligonucleotide therapy for Wilson disease
#2007Compositions and methods for modulation of SMN2 splicing in a subject
#2008Oligonucleotide compositions and methods thereof
#2009METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS
#2010Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
#2011Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
#2012Nucleic acid complex
#2013COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#2014Therapeutic method for huntington's disease
#2015METHODS AND COMPOSITIONS RELATED TO INCREASED ROTAVIRUS PRODUCTION
#2016Preparation and use of nanoparticle-doped RNA hydrogel targeting to triple negative breast cancer
#2017COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#2018Inhibitors of micro-RNA 22
#2019Micro-RNA and obesity
#2020METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION
#2021Nucleic acid molecules and methods of using the same
#2022Inhibition of polyomavirus replication
#2023Oligonucleotide analogues targeting human LMNA
#2024Nucleic acid with reduced toxicity
#2025Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
#2026Models of tauopathy
#2027Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
#2028Gene therapy of the FAAH pseudogene
#2029Methods and compositions for modulating apolipoprotein (a) expression
#2030Methods for modulating FMR1 expression
#2031LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SURVIVAL OF MOTOR NEURON (SMA) INHIBITORS
#2032Neurodegenerative disorders
#2033Selective antisense compounds and uses thereof
#2034Methods and compositions for macrophage polarization
#2035Antisense oligonucleotides rescue aberrant splicing of ABCA4
#2036METHODS OF MODULATING ANTISENSE ACTIVITY
#2037MODELING TDP-43 PROTEINOPATHY
#2038METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING METASTATIC TUMORS
#2039ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#2040Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy
#2041Loss of function alleles of PtEPSP-TF and its regulatory targets in rice
#2042Deoxynucleic Guanidines (DNG)- Modified Oligonucleotides and Methods of Synthesizing Deoxynucleic Guanidine Strands
#2043Long-chain non-coding RNA based BCL2 gene inhibitor
#2044TMPRSS6 iRNA compositions and methods of use thereof
#2045MODULATORS OF DNM2 EXPRESSION
#2046Conjugated antisense compounds and their use
#2047Direct and selective inhibition of MDM4 for treatment of cancer
#2048Compounds and methods for reducing SNCA expression
#2049Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#2050Method of Preparing Oligonucleotide Compounds
#2051Method for screening splicing variants or events
#2052METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USE
#2053OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
#2054METHODS OF MODULATING ALK
#2055Modified gapmer oligonucleotides and methods of use
#2056Antisense oligonucleotides targeting ATXN3
#2057Oversubscription scheduling
#2058Anti-C9ORF72 oligonucleotides and related methods
#2059Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#2060MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
#2061OLIGONUCLEOTIDES FOR MODULATING FNDC3B EXPRESSION
#2062POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#2063Selective Reduction of Allelic Variants
#2064METHODS AND COMPOSITIONS FOR GENERATING DOMINANT ALLELES USING GENOME EDITING
#2065Inhibitor for use for preventing and/or treating an infection with hepatitis B virus
#2066Reprogramming of non-neuronal cells into neurons and methods and compositions to treat neurodegenerative diseases and disorders
#2067CTLA-4 aptamer conjugates
#2068EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#2069Antisense oligonucleotides for modulating the function of a T cell
#2070Targeting cell tropism receptors to inhibit cytomegalovirus infection
#2071METHOD OF TREATING TYPE II DIABETES AND OBESITY AND METHOD OF SCREENING A MEDICAMENT FOR THE SAME
#2072Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2073Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#2074Methods of inducing insulin production
#2075Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
#2076Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics
#2077USE OF SINGLE-STRANDED ANTISENSE OLIGONUCLEOTIDE IN PREVENTION OR TREATMENT OF GENETIC DISEASES INVOLVING A TRINUCLEOTIDE REPEAT EXPANSION
#2078Modulating apolipoprotein (a) expression
#2079PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS
#2080OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#2081Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA
#2082Compositions and methods for treating motor neuron diseases
#2083Method for inhibiting the expression of cancer-promoting factors
#2084Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2085Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2086Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2087Compositions for modulating SOD-1 expression
#2088Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#2089ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
#2090Novel method of treating dystonia
#2091Oligonucleotides for inducing paternal UBE3A expression
#2092Use of leucine-zipper protein for diagnosis or treatment of fatty liver
#2093Compositions and methods for modulating dysferlin expression
#2094ANTI-TNF COMPOUNDS
#2095Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
#2096NUCLEIC ACID NANOSTRUCTURES WITH CORE MOTIFS
#2097ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE
#2098EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#2099Multivalent oligonucleotide assemblies
#2100ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS